ex-vivo gene therapy
data set in the world.
Medical professionals may also email us at firstname.lastname@example.org for more information about study participation.
† The lovo-cel clinical program is currently on a partial clinical hold pertaining to pediatric patients (under 18) related to an adolescent patient with persistent, non-transfusion-dependent anemia. bluebird bio, Inc. continues to work with the FDA to resolve the partial hold.